Impact of comorbidity on lung cancer survival

International Journal of Cancer

Volumn 103, Issue 6, 2003, Pages 792-802

  Tammemagi, C Martin ^a   Neslund Dudas, Christine ^a   Simoff, Michael ^b   Kvale, Paul ^b  

^a Josephine Ford Cancer Center   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Comorbidity; Lung cancer; Prognosis; Survival; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEMENTIA; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG CANCER; LUNG FIBROSIS; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; SMOKING; SURVIVAL RATE; SURVIVAL TIME; THYROID DISEASE; TUBERCULOSIS;

AGE DISTRIBUTION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; REGISTRIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 0037350139     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10882     Document Type: Article

References (75)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 1991;83: 1142-8.
3. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;24:504-14.
4. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996;77:2464-70.
5. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-83.
6. Yancik R. Epidemiology of cancer in the elderly. Current status and projections for the future. Rays 1997;22(Suppl 1):3-9.
7. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
8. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
9. Greenfield S. Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-70.
10. Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996;88:716-26.
11. West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 1996;6:413-9.
12. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-92.
13. Wells CK, Stoller JK, Feinstein AR, Horwitz RI. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984;144:2004-9.
14. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer 1991;67:2633-41.
15. Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998;82:2123-34.
16. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997;107:1469-75.
17. Sabin SL, Rosenfeld RM, Sundaram K, Har-el G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 1999;78:578-84.
18. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593-602.
19. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200.
20. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Le Marchand L. Smoking history and survival among lung cancer patients. Cancer Causes Control 1990;1:155-63.
21. Sobue T, Suzuki T, Fujimoto I, Doi O, Tateishi R, Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res 1991;82:33-9.
22. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
23. Langendijk JA, Thunnissen FB, Lamers RJ, de Jong JM, ten Velde GP, Wouters EF. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 1995;36:218-24.
24. Tammemagi M, McLaughlin J, Mullen J, Bull S, Johnston M, Tsao M-S, Casson A. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol 2000;10: 176-85.
25. Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer 1997;80:1482-8.
26. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998;21:105-13.
27. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer 2000;88:653-63.
28. Lopez-Encuentra A. Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer 2002;35: 263-9.
29. Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD, Patterson GA. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;123:280-7.
30. Clinical Classifications Software. Fact sheet. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2001. (http:www.ahrq.gov/data/hcup/ccsfact.htm)
31. Clinical Classifications Software (ICD-9-CM). Summary and download information. Rockville, MD: Agency for Healthcare Policy and Research, US Department of Health and Human Services, 2002. (http://www.ahrq.gov/data/ccs.htm)
32. U.S. Department of Health and Human Services. International classification of diseases, 9th rev. Clinical modification, 5th ed. vols. 1-3; DHHS publication PHS 94-1260. Washington DC: Public Health Service and Health Care Financing Administration, 1994.
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
34. Beahrs OH, ed. American Joint Committee on Cancer, American Cancer Society. Manual for staging of cancer, 4th ed. Philadelphia: Lippincott, 1992.
35. WHO. The World Health Organization histological typing of lung tumours, 2nd ed. Am J Clin Pathol 1982;77:123-36.
36. Kaplan D, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
37. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
38. Cox D. Regression models and life tables. J R Stat Soc 1972;34:187-220.
39. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
40. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989:79:340-9.
41. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven, 1998.
42. Hosmer DW Jr, Lemeshow S. Applied survival analysis - regression modeling of time to event data. New York: John Wiley & Sons. 1999.
43. Fujisawa T, Iizasa T, Saitoh Y, Sekine Y, Motohashi S, Yasukawa T, Shibuya K, Hiroshima K, Ohwada H. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 1999;17:2086.
44. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000;119:21-6.
45. Allison PD, SAS Institute. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995.
46. 2 measures based on Wald and likelihood ratio joint significance tests. Am Stat 1990;44:250-3.
47. 2 as a measure of goodness of fit. J R Stat Soc 1984;147:608-9.
48. 2. Am Stat 1985;39:279-85.
49. 2 in regression analysis. Biometrics 1987;43:61-9.
50. Korn EL, Simon R. Measures of explained variation for survival data. Stat Med 1990;9:487-503.
51. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med 1993;12:2377-82.
52. Schemper M, Stare J. Explained variation in survival analysis. Stat Med 1996;15:1999-2012.
53. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54:661-74.
54. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91:2214-21.
55. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22-36.
56. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93-105.
57. Pompei P, Charlson ME, Douglas RG Jr. Clinical assessments as predictors of one year survival after hospitalization: implications for prognostic stratification. J Clin Epidemiol 1988;41:275-84.
58. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453-71.
59. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387-404.
60. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol 1997;50:725-33.
61. Clemens JD, Feinstein AR, Holabird N, Cartwright S. A new clinicalanatomic staging system for evaluating prognosis and treatment of prostatic cancer. J Chronic Dis 1986;39:913-28.
62. Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, Har-El G, Lucente FE. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck 1998;20:1-7.
63. Piccirillo JF. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology (Huntingt) 1995;9:831-6, 41, 45-8.
64. Guadagnoli E, Shapiro C, Gurwitz JH, Silliman RA, Weeks JC, Borbas C, Soumerai SB. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer. J Clin Oncol 1997;15:2338-44.
65. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
66. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci 1998;53:M372-8.
67. Zincke H. Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994;12:2254-63.
68. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-7.
69. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74(Suppl 7):2101-6.
70. Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK. Edwards BK. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996;6:399-412.
71. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-6.
72. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CFD. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-48.
73. Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 1993:41:38-41.
74. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
75. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.